The primary goals were to assess the percentage change in body weight and the accomplishment of a weight loss of 5% by week 104
Very high-fiber foods in large quantities This one surprises people
Controlled data show an elevated rate: dizziness was reported in 18% of semaglutide users compared with 10% in the control group, indicating a clinically meaningful increase that supports active monitoring
Putting Semaglutide To The Test Scientists used a method called target trial emulation to pit semaglutide against seven other diabetes medications
Meet our doctors Last reviewed: 02 Jun 2026 Sources A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP) (STEP UP), Diabetes & endocrinology [accessed 26 September 2025] MHRA approves GLP1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults, GOV.UK [accessed 26 September 2025] Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval, Reuters [accessed 26 September 2025] Once-weekly semaglutide 72 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial, The Lancet [accessed 26 September 2025] Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen (PIL), emc [accessed 26 September 2025]
